Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on January 31, 2008

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008
Published online before print January 31, 2008, doi: 10.1161/ATVBAHA.107.160713
A more recent version of this article appeared on April 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Additional Materials
Right arrow Correction (v28,pe150)
Right arrow All Versions of this Article:
28/4/718    most recent
ATVBAHA.107.160713v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lombardi, A.
Right arrow Articles by Luconi, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lombardi, A.
Right arrow Articles by Luconi, M.

Submitted on July 24, 2007
Accepted on January 10, 2008

A New Mechanism Involving Erk Contributes to Rosiglitazone Inhibition of Tumor Necrosis Factor-{alpha} and Interferon-{gamma} Inflammatory Effects in Human Endothelial Cells

Adriana Lombardi ; Giulia Cantini ; Elisabetta Piscitelli ; Stefania Gelmini ; Michela Francalanci ; Tommaso Mello ; Elisabetta Ceni ; Gabriele Varano ; Gianni Forti ; Mario Rotondi ; Andrea Galli ; Mario Serio ; and Michaela Luconi *

From the DENOthe Center of Excellence for Research, Transfer and High Education: Department of Clinical Physiopathology (A.L., G.C., E.P., S.G., M.F., T.M., E.C., G.V., G.F., M.R., A.G., M.S., M.L.), University of Florence; and the Unit of Internal Medicine and Endocrinology (M.R.), Fondazione Salvatore Maugeri I.R.C.C.S., Pavia, Italy.

* To whom correspondence should be addressed. E-mail: m.luconi{at}dfc.unifi.it.

Objective—Microvascular endothelium is one of the main targets of the inflammatory response. On specific activation, endothelial cells recruit Th1-lymphocytes at the inflammatory site. We investigated the intracellular signaling mediating tumor necrosis factor (TNF)-{alpha} and interferon (INF)-{gamma} inflammatory response in human microvascular endothelial cells (HMEC-1) and the interfering effects of the peroxisome-proliferator-activated-receptor (PPAR{gamma}) agonist, rosiglitazone (RGZ).

Methods and Results—TNF{alpha} and IFN{gamma}, mainly when combined, stimulate IFN{gamma}-inducible protein of 10 kDa (IP10) and fractalkine production evaluated by ELISA and TaqMan analyses. This effect is not only mediated by activation of the NFkB and Stat1 classic pathways, but also involves a rapid increase in phosphorylation and activation of extracellular signal-regulated kinases (ERK1/2) as measured by Western blot. RGZ interferes with TNF{alpha} and IFN{gamma} stimulation of IP10, fractalkine, and adhesion molecule through a novel rapid mechanism which involves the blocking of ERK activation.

Conclusions—Our findings shed new light on the mechanisms underlying the inflammatory response of microvascular endothelium and on the possible therapeutic use of RGZ in vasculopathies involving Th1-responses.


Key words: thiazolidinediones • MAPK • CXCL10 • endothelium • Th1-response